I found this today which I hope is useful as it is very recent. thejournalofheadacheandpain...
European Headache Federation recommendations for ... - PMRGCAuk
European Headache Federation recommendations for neurologists managing giant cell arteritis - 17 Mch 2020
![Sefu profile image](https://images.hu-production.be/avatars/d5b599d100b841299bf415f8e227ab68_small@2x_100x100.jpg)
![Sefu profile image](https://images.hu-production.be/avatars/d5b599d100b841299bf415f8e227ab68_small@2x_100x100.jpg)
![DorsetLady profile image](https://images.hu-production.be/avatars/37bb6f16-7f5c-4826-80b7-4eb51bca8c53_small@2x_100x100.jpg)
Hi,
thank you.
Good to see they acknowledge that sight is still at risk within the first week of medication - that's not often mentioned, so can lead to a false sense of security.
But, they still are quoting being off Pred within 2 years without Tocilizumab and 1 year on it! Would like to see the figures on that actually happening.
Very interesting thanks for posting this
![PMRpro profile image](https://images.hu-production.be/avatars/0552c0a893f8293c57ee1b3703b6cef8_small@2x_100x100.jpg)
Nice and clear! A few interesting statements in it though - not least the presence of low/normal markers being associated with cranial GCA, that TAB is NOT particularly sensitive and "Both standard treatment with GC [40] and indeed licensed targeted treatment [41] for GCA confers significant risk of morbidity,"
Clear and interesting read. Thanks for posting!
Wow, a technical article written in Plain-ish English, shows it can be done. Interesting for me, especially about the diagnostics eg PET scan as I'm going to have one to see if I have LVV.